Review on Panax ginseng therapeutic efficacy for COVID-19-associated neurological diseases

In a recent review published in the Journal of Ginseng Research, researchers discussed the therapeutic potential of Panax ginseng for COVID-19 (coronavirus disease 2019)-induced neurological diseases.

Study: Panax ginseng as a potential therapeutic for neurological disorders associated with COVID-19; Toward targeting inflammasome. Image Credit: QinJin/Shutterstock
Study: Panax ginseng as a potential therapeutic for neurological disorders associated with COVID-19; Toward targeting inflammasome. Image Credit: QinJin/Shutterstock


SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) infections may cause a myriad of clinical manifestations involving multiple organ systems, including the nervous system (NS). NLRP3 (nucleotide-binding oligomerization domain-like receptor pyrin domain-containing-3) inflammasomes are multiprotein complexed that detect PAMPs (pathogen-associated molecular patterns) and DAMPs (damage-associated MPs) generated in neurological diseases.

P. ginseng is a conventional medicinal herb used widely for boosting immunity and treating several pathological NS disorders conditions. Recent studies have reported that the active components of P. ginseng (such as saponins and ginsenosides) could regulate the activation of NLRP3 inflammasomes in NS.

About the review

In the present study, researchers discussed existing literature concerning the SARS-CoV-2-induced neurodegeneration pathogenesis involving the activation of NLRP3 inflammasomes and the potential effectiveness of P. ginseng for NLRP3-targeted treatment of neurological diseases.

Neuropathogenesis of SARS-CoV-2 infections

Neurological diseases such as stroke and Alzheimer’s disease have increasingly been identified as consequences of SARS-CoV-2 infections. Neurological manifestations can be divided into musculoskeletal system manifestations, central NS (CNS) manifestations (such as headache, vertigo, stroke, ataxia, anosmia, and seizures), and peripheral NS (PNS) manifestations (such as neuropathic pain and smell/vision/taste impairments).

SARS-CoV-2 invades the NS via two mechanisms: (i) SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) receptors or modifies the tight junction proteins between the adjacent BBB (blood-brain barrier) endothelial cells or (ii) SARS-CoV-2 is phagocytosed by immunological cells and subsequently invades the CNS by the hematogenous or non-hematogenous spread.

In response to SARS-CoV-2-associated neurological injury and associated PAMP and DAMP formation, NLRP3 inflammasome is assembled and activated, stimulating the production of caspase-1-mediated interleukin (IL)-1β, IL-18, and other cytokines such as IL-6,12, and tumor necrosis factor-alpha (TNF-α) by immunological cells. Therefore, NLP3 could be targeted to develop anti-SARS-CoV-2 therapeutic agents.

NLRP3 assembly involves two phases, priming, and activation. The priming phase is triggered by the signaling of pattern recognition receptors, such as toll-like receptors (TLRs) and TNF receptors (TNFRs). Receptor activation causes transcriptional activation of pro-IL-18, pro-IL-1β and NLRP3 via NF-κB (nuclear factor kappa B)-mediated transcriptional regulation.

The second step involves NLRP3 and ASC assembly into the inflammasome multiprotein complex initiated by ionic flux-stimulated NLRP3 stimulation (K+ and CL- efflux, Ca+ and Na+ influx), mitochondrial dysfunction, reactive oxygen species (ROS), lysosomal injury, adenosine triphosphate (ATP), and caspase-1 activation.

NLRP3 inflammasomes are initially expressed in inflammatory and immunological cells, including microglia, neutrophils, macrophages, and mast cells. Microglia are key cells involved in neuroinflammation, and balancing the M1(inflammatory)/M2 (anti-inflammatory) microglia polarization is a potential therapeutic strategy for COVID-19-associated neurodegeneration.

Currently used approaches

Antiviral drugs such as paxlovid, remdesivir, and molnupiravir have been effective against SARS-CoV-2; however, they are associated with adverse effects. The most frequent side effects of remdesivir use include pulmonary failure, and organ dysfunction, with lowered albumin and potassium levels and erythrocyte and platelet counts, contributing to yellowish skin discoloration and blood clot formation.

P. ginseng is a medicinal herb with anti-inflammatory/oxidant/aging/neurodegenerative, restorative activities, and cognitive and memory-enhancing activities with fewer side effects than the currently used antiviral drugs. The herb has demonstrated efficacy against influenza and pneumonia in several in vivo studies. Korean red ginseng (KRG) extract (KRGE) inhibits IL-1β and caspase-1 production and ASC (apoptosis-associated speck-like protein with CARD domain) pyroptosome formation.

The herb’s saponins inhibit NLRP3 and pro-IL-1β transcription and translation at the initial (priming) step. KRGE saponins have shown anti-inflammatory effects by ameliorating the messenger ribonucleic acid (mRNA) expression of genes encoding NLRP3 inflammasome components such as pro-IL-1β and pro-caspase-1 in mice. Ginsenoside Rd, a component of P. ginseng, reduces OGD/R (oxygen-glucose deprivation/reoxygenation)-induced BV-2 microglial cell injury by suppressing NLRP3 inflammasome activation and inhibiting dynamin-associated protein 1-mediated mitochondrial fission.

Ginsenoside Rg1 inhibits IL-1β-induced neuroinflammation by regulating NF-κB pathways, inhibits microglia pyroptosis, and inhibits NLRP3 inflammasome production by regulating the signal transducer and activator of transcription 2 (STAT2) pathway. Ginsenoside Rh1 and Rg3 reduce IL-1β production induced by LPS and downregulate NLRP3 inflammasomes. Compound K (secondary ginsenoside), and Notoginsenoside R1 (P. notoginseng component) can ameliorate oxidative stress.

Non-saponin components downregulate TLR4 mRNA and protein expression and attenuate cytokine production. GEF (gintonin-enriched fraction) suppresses NLRP3 expression through lysophosphatidic acid receptors (LPARs). Further, CPA (combination of P. ginseng and Angelica sinensis) and ginsenoside Rd- Z-ligustilide combinations reduce NLRP3 inflammasome activation.

Overall, the review findings highlighted the potential therapeutic use of P. ginseng for neurological diseases associated with SARS-CoV-2 infections via NLRP3 inflammasome regulation.

Journal reference:
Pooja Toshniwal Paharia

Written by

Pooja Toshniwal Paharia

Pooja Toshniwal Paharia is an oral and maxillofacial physician and radiologist based in Pune, India. Her academic background is in Oral Medicine and Radiology. She has extensive experience in research and evidence-based clinical-radiological diagnosis and management of oral lesions and conditions and associated maxillofacial disorders.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Toshniwal Paharia, Pooja Toshniwal Paharia. (2022, October 14). Review on Panax ginseng therapeutic efficacy for COVID-19-associated neurological diseases. News-Medical. Retrieved on June 21, 2024 from

  • MLA

    Toshniwal Paharia, Pooja Toshniwal Paharia. "Review on Panax ginseng therapeutic efficacy for COVID-19-associated neurological diseases". News-Medical. 21 June 2024. <>.

  • Chicago

    Toshniwal Paharia, Pooja Toshniwal Paharia. "Review on Panax ginseng therapeutic efficacy for COVID-19-associated neurological diseases". News-Medical. (accessed June 21, 2024).

  • Harvard

    Toshniwal Paharia, Pooja Toshniwal Paharia. 2022. Review on Panax ginseng therapeutic efficacy for COVID-19-associated neurological diseases. News-Medical, viewed 21 June 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Several key policies to stop the spread of COVID-19 were generally a good idea in hindsight according to majority of Americans